HDAC6 inhibitors are effective chemotherapy agents that modulate protein acetylation, boost p21 gene expression, and hinder tumor growth through cell differentiation or apoptosis.

TC BioPharm PLC, a clinical-stage biotech company focused on allogeneic gamma-delta T cell cancer therapies, has announced FDA approval for its investigational new drug application to enter a Phase 1B trial for recurrent and refractory Acute Myeloid Leukemia.

Interim results from a human trial on PLB-1004 presented at the 2023 AACR Congress highlight its clinical promise.

The first participant has been dosed in OncoNano Medicine's Phase 1 trial of ONM-501 for individuals with advanced solid cancers and lymphomas.

KRAS G12C is a specific mutation of the KRAS gene that plays a crucial role in the development and progression of certain cancers.

Acadia Pharmaceuticals Inc. announces Phase 2 trial to test efficacy and safety of ACP-204 for Alzheimer's-related psychosis hallucinations and delusions.

On 14 Apr 2023, the data from phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors was updated at the AACR Congress.

Genmab A/S provided updates on FDA and EMA regulatory progress concerning their bispecific T-cell engaging antibody, epcoritamab, which is administered subcutaneously and under review.

IL-6 inhibitors work by blocking the binding of IL-6 to the IL-6 receptor, inhibiting the signal transduction of IL-6, and thereby reducing the inflammatory response in patients. Several IL-6 inhibitors have been approved for use worldwide.

GSK reports encouraging outcomes from the DREAMM-7 phase III comparative study of Blenrep for recurrent or resistant multiple myeloma.

Preliminary findings from the phase I study on Orca-T cell therapy with tacrolimus in RIC will be presented at ASH 2023, showcasing its promise.

Formycon AG, in collaboration with its licensing associate Klinge Biopharma GmbH, has declared the submission of the commercial application for FYB203 to the European Medicines Agency.